-
Post-menopausal Osteoporosis Pipeline Report: In-depth Analysis into the Clinical Trials, Emerging Drugs, and Treatment Outlook | Key Companies – Sandoz, Amgen, Pfizer, Eli Lilly, and Others
30 Dec 2021 22:37 GMT
… -menopausal Osteoporosis Treatment.
Post-menopausal Osteoporosis key … .
Post-menopausal Osteoporosis Drugs under development based … ;university websites, clinical trial registries, conferences, SEC … Osteoporosis Market include:
Sandoz
Haoma Medica
Amgen
Pfizer …
-
Osteoporosis Market to Register Incremental Growth During the Forecast Period 2030, Asserts DelveInsight | Key Companies – Amgen, Pfizer, Roche, Novartis, Pfenex, Haoma Medica, Eli Lilly, and Others
13 Dec 2021 23:35 GMT
… The Osteoporosis market report covers emerging drugs, current treatment … Osteoporosis Market include:
Amgen
Haoma Medica
Pfizer
Radius Health
TherapeuticsMD
Roche
Novartis Pharmaceuticals … -aqqg)
Prolia (Denosumab)
Fablyn (Lasofoxifene)
Duavee (conjugated …
-
The Present and Future of Endocrine Therapy in Breast Cancer
24 Oct 2024 20:43 GMT
… 3
Several ongoing clinical trials are also exploring … lasofoxifene [Fablyn], which is a tamoxifen-like drug. It … from the MONARCH-E trial [NCT03155997] suggesting there … Pfizer’s vepdegestrant (ARV-471) receives FDA fast track designation for the treatment …
-
Selective estrogen receptor modulators (SERMs) Market Dynamics: Significant Expansion Anticipated, 2034 | DelveInsight
26 Dec 2024 16:50 GMT
… involve extensive clinical trials to demonstrate … drug market.
Several major pharmaceutical companies, including Duchesnay, Pfizer, … for the treatment of osteoporosis in postmenopausal … . Similarly, Sermonix Pharmaceuticals' FABLYN has already been …
-
Lasofoxifene Shows Promise in Lowering Ki-67 Levels in HR+/HER2- Breast Cancer
06 Nov 2024 16:44 GMT
… was observed with lasofoxifene (Fablyn) treatment, according to findings … Cancer conference. The trial enrolled 20 patients in … of the I-SPY2 trial, patients were enrolled … an upcoming medical meeting.
REFERENCES:
1. Sermonix Pharmaceuticals’ lasofoxifene …
-
Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor
03 May 2016 13:43 GMT
… Pharmaceuticals and Pfizer. Pfizer developed the oral form of lasofoxifene tartrate for osteoporosis … Europe for osteoporosis treatment by the EMEA … trials and was actively involved during the drug… focus on FDA regulatory issues, clinical trial conduct, …
-
Sermonix Pharmaceuticals to Give Lasofoxifene Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease
31 Mar 2016 14:04 GMT
… drug, suggest that lasofoxifene is an attractive treatment … GARNET and CORAL trials, is an investigational … Officer and Chief Medical Officer of Sermonix. … Pharmaceuticals and Pfizer. Pfizer developed the oral form of lasofoxifene tartrate for osteoporosis …
About
© 1995-2025